FS Medical Supplies, LLC v. TannerGAP, Inc.

CourtDistrict Court, W.D. North Carolina
DecidedFebruary 13, 2024
Docket3:21-cv-00501
StatusUnknown

This text of FS Medical Supplies, LLC v. TannerGAP, Inc. (FS Medical Supplies, LLC v. TannerGAP, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FS Medical Supplies, LLC v. TannerGAP, Inc., (W.D.N.C. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF NORTH CAROLINA CHARLOTTE DIVISION 3:21-cv-00501-RJC-WCM

FS MEDICAL SUPPLIES, LLC, ) ) Plaintiff, ) ) MEMORANDUM AND ) RECOMMENDATION v. ) ) TANNERGAP, INC. and ) TANNER PHARMA UK LIMITED, ) ) Defendants. ) _____________________________________ )

This matter is before the Court on Plaintiff’s Motion to Consolidate (the “Motion to Consolidate,” Doc. 127) by which Plaintiff moves to consolidate this action (“Tanner I”) with FS Medical Supplies, LLC v. Tanner Pharma UK Limited, Raymond Fairbanks Bourne, and Mary Everett Whitehurst Bourne, No. 3:23-cv-00598-RJC-WCM (“Tanner II”). It is also before the undersigned for the issuance of recommendations regarding various pretrial scheduling and discovery matters. I. Background A. Tanner I, No. 3:21-cv-00501-RJC-WCM. On September 23, 2021, FS Medical Supplies, LLC (“FSMS”) filed its original complaint in the instant matter naming TannerGAP, Inc. (“GAP”) and Tanner Pharma UK, Limited (“TPUK”) (collectively, “Tanner”) as defendants. Doc. 1. Generally, FSMS asserts claims based on Tanner’s alleged breaches of a Non-Circumvention Agreement and a Distribution Agreement related to the

sale of COVID-19 rapid tests. On September 16, 2022, FSMS filed an Amended Complaint that added Raymond Fairbanks Bourne (“Bourne”) and Stephen John Scalia (“Scalia”) as defendants. See Doc. 58.1

On September 30, 2023, motions to dismiss filed by Tanner were granted in part and motions to dismiss filed by Bourne and Scalia were granted. The claims remaining in Tanner I are breach of the Distribution Agreement and breach of the Non-Circumvention Agreement against Tanner. See Doc. 117 at

3, 16. On October 31, 2023, the parties filed a Joint Certification of Initial Attorneys’ Conference and Discovery Plan. Doc. 123. On December 19, 2023, FSMS filed the Motion for Consolidation. Tanner

responded, and FSMS replied. Docs. 129, 136.

1 Bourne is the sole officer of GAP, the sole director of TPUK, and the owner of 75% of the shares of TPUK. Tanner I, Doc. 58 at 3. Scalia is described as being the “President of ‘Tanner Pharma Group’…” Id. FSMS alleges that Bourne and Scalia “direct, control, and coordinate the activities of [Tanner] ….” Id. at 4. B. Tanner II, No. 3:23-cv-00598-RJC-WCM On September 20, 2023, FSMS filed its original complaint against

Bourne and Mary Everett Whitehurst Bourne a/k/a Molly Bourne (the “Bourne Defendants”) and TPUK. Tanner II, Doc. 1. On October 5, 2023, FSMS filed an Amended Complaint against these same defendants. Doc. 33. Generally, FSMS alleges that Bourne fraudulently

conveyed TPUK’s assets to the Bourne Defendants thereby “stripping the company of sufficient assets to pay FSMS.” Doc. 33 ¶ 1. More specifically, FSMS contends that it learned, on March 31, 2023, that TPUK disbursed a total of $96,700,000.00 to the Bourne Defendants beginning in January 2021,

and that it learned on September 29, 2023, that FSMS had disbursed another $100,000,000.00 in dividends to the Bourne Defendants on March 8, 2022. See Doc. 39 at 3. FSMS also filed a Motion for Temporary Restraining Order and

Preliminary Injunction, which sought to stop the issuance of any future dividends and to freeze dividends previously disbursed to the Bourne Defendants. Doc. 5. On October 16, 2023, FSMS’s request for injunctive relief was denied.

Doc. 39. On November 15, 2023, the parties filed a Joint Certification of Initial Attorneys’ Conference and Discovery Plan. Doc. 44. Therein, the parties again outlined their positions for and against the consolidation of Tanner I and Tanner II.

C. January 17, 2024 Proceedings On January 17, 2024, the undersigned conducted a hearing on multiple motions, as well as a combined initial pretrial conference in both Tanner I and Tanner II.2

II. The Motion to Consolidate As noted, by the Motion to Consolidate, FSMS asks that Tanner I and Tanner II be consolidated. During the hearing on January 17, FSMS acknowledged that some of the evidence in each case would be different, but it

nonetheless contends that trying both matters separately would result in the duplication of testimony. Further, FSMS asserts that the question of how trial will ultimately be conducted (including whether the issues in Tanner II are bifurcated) is separate from whether these matters should be “generally”

consolidated at this time. Tanner responds that while Tanner I is a breach of contract case, Tanner II would involve different testimony regarding different timeframes; specifically, evidence regarding the distributions from TPUK to the Bourne

Defendants. Tanner further asserts that consolidated discovery would be

2 Besides the Motion to Consolidate, the undersigned heard Motions to Compel filed in Tanner I and Tanner II, as well as other motions related to sealing and page limits. difficult to manage because of the different relevant time periods and claims. Finally, Tanner agrees that coordination of discovery across both cases is

appropriate, but it contends that the trial in Tanner II should be set for a date following the trial in Tanner I.3 The Bourne Defendants generally agree with Tanner’s positions regarding consolidation. Rule 42 of the Federal Rules of Civil Procedure provides that, “[i]f actions

before the court involve a common question of law or fact, the court may: (1) join for hearing or trial any or all matters at issue in the actions; (2) consolidate the actions; or (3) issue any other orders to avoid unnecessary cost or delay.” Fed. R. Civ. P. 42(a). “The consolidation of actions is ordinarily within the

discretion of the trial court.” Pickens v. Hendricks, No. 1:21-cv-00030-MR, 2023 WL 316134, at *3 (W.D.N.C. Jan. 19, 2023) (citing Mut. Life Ins. Co. v. Hillmon, 145 U.S. 285, 292 (1892)). “[P]roper application of Rule 42(a) requires the district court to determine ‘whether the specific risks of prejudice and possible

confusion’ from consolidation [are] ‘overborne by the risk of inconsistent adjudications ..., the burden on parties, witnesses, and available judicial resources posed by multiple lawsuits, the length of time required to conclude multiple suits as against a single one, and the relative expense to all concerned

of the single-trial, multiple-trial alternatives.’” Campbell v. Boston Scientific

3 The parties appear to be in agreement that a finding of no liability in Tanner I would obviate the need for a trial in Tanner II. Corp., 882 F.3d 70, 74 (4th Cir. 2018) (quoting Arnold v. Eastern Air Lines, Inc., 681 F.2d 186, 193 (4th Cir. 1982), , 712 F.2d 899

(4th Cir. 1983) (en banc)). Here, the specific legal claims asserted in each case are not identical; Tanner I involves contract claims against Tanner while Tanner II involves claims relative to the alleged wrongful distribution of corporate dividends.

Nonetheless, there are many facts that will overlap; indeed, a copy of the Amended Complaint in Tanner I is attached to the Amended Complaint in Tanner II and is incorporated by reference in the Amended Complaint in Tanner II. Doc. 33 at ¶ 15.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
FS Medical Supplies, LLC v. TannerGAP, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fs-medical-supplies-llc-v-tannergap-inc-ncwd-2024.